Joseph W. Landry, Ph.D.
Massey Cancer Center research program membership
Department of Human and Molecular Genetics,
School of Medicine
PhD, Stony Brook University, SUNY (2002)
We study epigenetic regulatory mechanisms of tumor cell immunogenicity. These mechanisms serve to suppress tumor cell immunogenicity, which in turn suppress the anti-tumor immune response. By studying these mechanisms, we hope to discover novel drug targets, which can be exploited as cancer therapies. Our current focus is on the chromatin remodeling factor NURF, which we have discovered to regulate both the adaptive and innate immune response to tumor cells.
Disease focus of research
Animal models,Cancer cell biology,Drug discovery,Epigenetics,Immunotherapy,Metabolism,Targeted therapies,Tumor microenvironment
Published research (during tenure as a Massey Cancer Center member)
Search In PubMed